## **Core Concept**
The question targets the treatment options for metastatic hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. This specific subtype of breast cancer expresses hormone receptors (estrogen and/or progesterone receptors) but lacks HER2 overexpression. Treatment often focuses on targeting the hormone receptors.

## **Why the Correct Answer is Right**
The correct answer, **Palbociclib**, is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It works by inhibiting the progression from the G1 phase to the S phase of the cell cycle, thereby reducing tumor growth. Palbociclib is specifically used in combination with endocrine therapy (e.g., letrozole) for the treatment of HR+, HER2- advanced or metastatic breast cancer. This combination leverages the synergistic effect between hormone therapy and CDK4/6 inhibition, significantly improving progression-free survival in patients.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although not specified, other drugs might be used in breast cancer treatment, they are not the recent addition specifically for HR+, HER2- metastatic breast cancer as described.
- **Option B:** Similarly, without specifics, this option does not align with the recent therapeutic approach for HR+, HER2- metastatic breast cancer focusing on CDK4/6 inhibition.
- **Option D:** This option is incorrect as it does not represent a drug class or specific agent recently approved or commonly used for this indication.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Palbociclib** and similar CDK4/6 inhibitors (like Ribociclib and Abemaciclib) have revolutionized the treatment of HR+, HER2- metastatic breast cancer by significantly improving outcomes when used with endocrine therapy. These drugs represent a critical shift towards more targeted therapies.

## **Correct Answer Line**
**Correct Answer: C. Palbociclib.**